The present invention relates to an inhalable pharmaceutical composition for treating asthma, containing salbutamol as the active ingredient, and also containing excipients such as a surfactant, an isosmotic agent, a diluent, a viscosity enhancer, a preservative and a pH adjusting agent.
PARENTERAL PHARMACEUTICAL FORMULATION IN SUSPENSION, HAVING SUSTAINED RELEASE, IN LOW AND ULTRALOW DOSAGE, IN HORMONAL THERAPY IN THE CLIMACTERIC SYNDROME
Parenteral pharmaceutical formulation or composition, in suspension, having sustained release, containing suspended particles of estradiol and progesterone for hormonal replacement in female mammals in low and ultralow dosage; the formulation consists of an injectable suspension comprising particles of estradiol, particles of progesterone, a surfactant agent, an isosmotic agent, a thickening agent, and one or more preservation agents, wherein the estradiol is in particles having a size between 1 and 100 microns and the progesterone is in particles having a size between 1 and 100 microns, for application thereof in parenteral, intramuscular, subcutaneous or intradermal pharmaceutical form.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
PARENTERAL PHARMACEUTICAL FORMULATION IN SUSPENSION, HAVING SUSTAINED RELEASE, IN LOW AND ULTRALOW DOSAGE, IN HORMONAL THERAPY IN THE CLIMACTERIC SYNDROME
Parenteral pharmaceutical formulation or composition, in suspension, having sustained release, containing suspended particles of estradiol and progesterone for hormonal replacement in female mammals in low and ultralow dosage; the formulation consists of an injectable suspension comprising particles of estradiol, particles of progesterone, a surfactant agent, an isosmotic agent, a thickening agent, and one or more preservation agents, wherein the estradiol is in particles having a size between 1 and 100 microns and the progesterone is in particles having a size between 1 and 100 microns, for application thereof in parenteral, intramuscular, subcutaneous or intradermal pharmaceutical form.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
PHARMACEUTICAL COMPOSITION COMPRISING N-SULPHOETHYLNICOTINAMIDE USEFUL IN TREATMENT OR PREVENTION OF A PULMONARY DISEASE AND USE OF SAID COMPOSITION FOR TREATMENT OR PREVENTION OF SAID DISEASE
The present invention concerns a compound for treating or preventing a pulmonary disease, the compound having the following formula: N-sulphoethylnicotinamide (NESA, [N-nicotinamide] - ethanesulphonic acid 2) and the pharmaceutically acceptable derivatives thereof. In a preferred embodiment of the invention a pharmaceutical composition comprises the compound N-sulphoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. The purpose of the composition is to treat or prevent a pulmonary disease. In particular, the composition comprises between approximately 7 mg and approximately 1 g of N-sulphoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. Preferably, the composition comprises between approximately 140 mg and approximately 800 mg of N-sulphoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. More preferably, the composition comprises between approximately 250 mg and approximately 500 mg of N-sulphoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof.
A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
A61P 11/00 - Drugs for disorders of the respiratory system
6.
N-SULPHOETHYLNICOTINAMIDE, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF FOR INHIBITING OR PREVENTING UNWANTED FORMATION OF FIBROUS TISSUE
The present invention refers to a novel compound which inhibits, avoids or prevents unwanted formation of fibrous tissue which has the following structural formula: N-sulphoethylnicotinamide (NESA, ethanesulphonic acid 2 - [N-nicotinamide]) and the pharmaceutically acceptable derivatives thereof. In one particular embodiment of the invention a pharmaceutical composition which comprises the compound N-sulphoethylnicotinamide (NESA) or a pharmaceutically acceptable derivative thereof. In accordance with the present invention, the pharmaceutical composition which includes NESA can be administered by any of the following means: oral, inhalatory, intranasal, parenteral, intrarectal, intravenous, intramuscular, subcutaneous, intrathecal, intra-articular, transcoelomic, intralesional and percutaneous.
The present invention concerns a method for preparing a salt of ethanesulphonic acid 2-[N-nicotinamide] comprising at least one step wherein the triethylammonium salt of ethanesulphonic acid 2-[N-nicotinamide] is obtained. A specific embodiment of the invention is a method for preparing the triethylammonium salt of ethanesulphonic acid 2-[N-nicotinamide] which involves obtaining the mixed anhydride of nicotinic acid and alkyl chloroformiate, and making said mixed anhydride react with taurine in the presence of triethylamine.
C07C 309/15 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups X being a hetero atom, Y being any atom
C07C 303/32 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
